14. UnitedHealth Group (UNH)
Number of Hedge Funds: 145 (2025Q4)
Number of Hedge Funds: 140 (2025Q3)
UnitedHealth Group (UNH) is navigating a period of significant institutional re-evaluation. While major “anchor” investors remain committed, the stock has faced downward pressure following lowered guidance, leading to some high-profile exits and target cuts.
1. Hedge Fund Activity: Divergence Among Titans
Hedge fund sentiment is currently split between those locking in gains and those doubling down on the lower valuation:
- The Major Exits: Aristotle Growth Equity Fund completely exited its position in UNH during Q4 2025/Q1 2026, citing the company’s lowered guidance as a primary reason for no longer meeting their growth criteria.
- The High-Conviction “Holds”: Despite the volatility, Warren Buffett (Berkshire Hathaway) maintains a position of over 5 million shares (~$1.66 billion). Ken Fisher (Fisher Asset Management) actually increased his stake slightly (+1%), while Boykin Curry (Eagle Capital) boosted his position by 6%.
- Options Activity: Ken Griffin (Citadel) is highly active in the name but shows a cautious bias, recently trimming his “Call” exposure by 13% while maintaining a massive “Put” position valued at over $3.1 billion.
2. Analyst Upgrades & Investor Letter Sentiment
The narrative for 2026 has shifted toward a “show-me” story as analysts digest recent headwinds:
- Mizuho Target Cut: On February 5, 2026, Mizuho significantly lowered its price target for UNH from $430 to $350, reflecting concerns over the company’s weak guidance, though it maintained an “Outperform” rating.
- The “Bull Case” Theory: Some boutique analysts (such as DIY Investor) remain bullish, arguing that UNH is one of the best long-term retirement stocks due to its strengthening healthcare platform and the continued expansion of Optum.
- Sequoia Strategy Perspective: In their Q4 2025 letter, Ruane, Cunniff LP (Sequoia) noted that the stock has faced a difficult stretch, dropping nearly 14% since the start of 2026, which has led to a lower valuation that some value-oriented funds find attractive.
3. Insider Trading: opportunistic Buying vs. Programmatic Sells
The insider roster shows a mix of opportunistic purchases during price dips and routine sells:
- Major Internal Support: In May 2025, several top insiders bought shares during a significant dip. J. Stephen Hemsley (Director/Former CEO) made a massive purchase of 86,700 shares at $288.57 (totaling over $25 million). John Rex (President & CFO) also bought over $4.9 million worth of shares at $291.12.
- Routine Selling: More recent activity in late 2025 and early 2026 has been dominated by directors and officers selling at higher prices, such as D. Charles Baker and Hugh Patrick Conway, though these transactions have been relatively small compared to the mid-2025 buy-in.
- Recent Active Roster: As of late February 2026, the Chief Accounting Officer (E. Thomas Roos) and Chief Legal Officer (R. Christopher Zaetta) have filed active transactions, suggesting a period of high-level equity management following the latest guidance.
Summary Verdict
UnitedHealth is currently a “Consensus Value Turnaround” play. The 13% reduction in Calls from Citadel and the exit by Aristotle Funds signal that growth-focused momentum is cooling. However, the $25 million purchase by Stephen Hemsley at the sub-$300 level and the continued backing of Warren Buffett suggest that the “smart money” sees a strong floor at current valuations.
